Amycretin
Regulatory
Legal Status in 2026
In active US clinical trials (Phase 2 or later); no FDA approval yet.
This compound is under active investigation in US clinical trials (Phase 2 or later) and has not yet received FDA approval. It is not legally available for prescription or compounding outside of enrolled clinical trial settings. The risk-benefit profile is not yet established for the general population.
About
About Amycretin
Amycretin is a unimolecular fusion peptide combining GLP-1 receptor agonism with amylin receptor agonism in a single molecule, developed by Novo Nordisk as the next evolution beyond semaglutide. Phase I data showed extraordinary weight loss of approximately 13% over just 12 weeks — suggesting potential for 25%+ reductions at full treatment duration. It represents the first clinically advanced GLP-1/amylin combination in a single molecular entity.
Science
Mechanism of Action
Simultaneously activates GLP-1 receptors to suppress appetite and slow gastric emptying, and amylin receptors in the area postrema and hypothalamus to independently reduce food intake and body weight through complementary and additive satiety pathways.
Dosing
Typical Protocol
Weekly subcutaneous injection; Phase I doses not publicly disclosed; Phase II ongoing as of 2025.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Availability
Provider availability
Amycretin is in active clinical trials and is not available through legitimate US prescribing or compounding channels outside an enrolled trial, so Vial does not list providers for it.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.